Loading...
•
Dec 31, 2019
Myriad Genetics Q2 2020 Earnings Report
Reported financial results for the second quarter of fiscal year 2020.
Key Takeaways
Myriad Genetics reported a total revenue of $195.1 million for the second quarter of fiscal year 2020, a 10% decrease compared to the same period last year. The company's diluted EPS was ($0.11), while the adjusted EPS was $0.23.
Total second-quarter revenues were $195.1 million.
Second-quarter diluted EPS was ($0.11) and adjusted EPS was $0.23.
Signed a fixed-price portfolio contract with UnitedHealthcare.
Received FDA approval for BRACAnalysis CDx as a companion diagnostic test for patients with metastatic pancreatic cancer seeking treatment with Lynparza.
Revenue by Segment
Forward Guidance
Myriad Genetics provided financial guidance for fiscal year 2020 and the third quarter of 2020.
Positive Outlook
- Revenue for fiscal year 2020 is expected to be $735 million.
- Adjusted earnings per share for fiscal year 2020 is expected to be $0.45.
- Revenue for the third quarter of 2020 is expected to be $172 million.
- Adjusted earnings per share for the third quarter of 2020 is expected to be $0.02.
Challenges Ahead
- GAAP diluted earnings per share for fiscal year 2020 is expected to be ($0.80).
- GAAP diluted earnings per share for the third quarter of 2020 is expected to be ($0.30).
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...